Trulicity (dulaglutide) and Victoza (liraglutide) are prescription drugs prescribed to lower blood sugar levels and certain cardiovascular risks. Both drugs come as liquid solutions that are given as ...

Trulicity helps lower blood sugar in adults and children ages 10 years and older with type 2 diabetes. It also may reduce major heart risks in adults with type 2 diabetes who have or are at risk for ...

Once-weekly treatment for adults with type 2 diabetes comes in a pen with a no-see, no-handle needle INDIANAPOLIS, Nov. 10, 2014 /PRNewswire/ -- The newest GLP-1 receptor agonist treatment option to ...

The Food and Drug Administration (FDA) has approved Trulicity (dulaglutide; Eli Lilly) pen as adjunct to diet and exercise to improve glycemic control in in adults with type 2 diabetes. Dulaglutide, a ...

Trulicity, a weekly glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for adults with type 2 diabetes as an adjunct to diet and exercise The single-dose pen does not require mixing nor ...

Some of the Trulicity app’s features include medication reminders, a virtual demo of the Trulicity pen, live chats to answer questions in real-time, videos, and access to a savings card. To have a ...

INDIANAPOLIS, June 13, 2020 /PRNewswire/ -- New real-world data showed Trulicity® (dulaglutide) had significantly higher adherence and longer persistence compared to weekly injections of semaglutide ...

Eli Lilly and Company has developed an app for people living with Type II diabetes who use Trulicity, the company’s once-per-week injectable diabetes medication that also works with a click-activated ...

Eli Lilly has launched its once-weekly diabetes therapy Trulicity in the US, hoping to break into the fast growing, competitive GLP-1 agonist market. Trulicity (dulaglutide) was approved by the FDA at ...

AWARD-11 showed 3.0 mg and 4.5 mg doses led to additional blood sugar control; as a secondary endpoint, both doses also led to weight loss INDIANAPOLIS, Sept. 3, 2020 /PRNewswire/ -- The U.S. Food and ...

TORONTO, Feb. 16, 2016 /CNW/ - Eli Lilly Canada announced the approval of Trulicity™ (dulaglutide), a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of adults ...